Published in Nephrol Dial Transplant on July 08, 2009
Roles of the immune system in skin cancer. Br J Dermatol (2011) 1.12
The role of the immune response in merkel cell carcinoma. Cancers (Basel) (2013) 0.91
The conundrum of causality in tumor virology: the cases of KSHV and MCV. Semin Cancer Biol (2013) 0.89
Merkel cell carcinoma in immunosuppressed patients. Cancers (Basel) (2014) 0.86
Merkel cell carcinoma: interdisciplinary management of a rare disease. J Skin Cancer (2013) 0.83
Defective DNA repair and cell cycle arrest in cells expressing Merkel cell polyomavirus T antigen. Int J Cancer (2012) 0.83
Merkel cell carcinoma. Am J Clin Oncol (2013) 0.83
miRNA-34a underexpressed in Merkel cell polyomavirus-negative Merkel cell carcinoma. Virchows Arch (2014) 0.81
Merkel cell carcinoma of the head and neck: pathogenesis, current and emerging treatment options. Onco Targets Ther (2015) 0.79
Merkel cell carcinoma: a population-based study on mortality and the association with other cancers. Cancer Causes Control (2011) 0.79
Merkel cell carcinoma of left groin: a case report and literature review. Case Rep Oncol Med (2013) 0.77
Comparison of the incidence of skin cancers in patients on dialysis and after kidney transplantation. Postepy Dermatol Alergol (2017) 0.75
A rapidly growing lid lump. BMJ Case Rep (2014) 0.75
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 11.33
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol (2008) 6.43
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol (2006) 6.00
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA (2012) 5.00
Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA (2003) 4.01
Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst (2005) 3.73
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res (2002) 3.70
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma. J Natl Cancer Inst (2009) 3.17
MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science (2011) 3.17
Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst (2005) 3.07
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol (2006) 2.81
Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology (2005) 2.80
Comparison of solution-based exome capture methods for next generation sequencing. Genome Biol (2011) 2.78
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol (2013) 2.70
Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst (2007) 2.70
Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer. Radiother Oncol (2006) 2.66
Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol (2002) 2.63
KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol (2004) 2.61
Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology (2006) 2.50
NORDCAN--a Nordic tool for cancer information, planning, quality control and research. Acta Oncol (2010) 2.48
Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst (2002) 2.44
Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet (2003) 2.43
The Finnish Cancer Registry as follow-up source of a large trial cohort--accuracy and delay. Acta Oncol (2002) 2.40
Night work and breast cancer risk: a systematic review and meta-analysis. Eur J Cancer (2005) 2.35
Personality traits and cancer risk and survival based on Finnish and Swedish registry data. Am J Epidemiol (2010) 2.30
Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol (2007) 2.17
Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol (2005) 2.17
Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol (2009) 2.16
Statins and cancer: A systematic review and meta-analysis. Eur J Cancer (2008) 2.15
Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer (2010) 2.11
Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst (2007) 2.08
Risk of malignant neoplasms after liver transplantation: a population-based study. Liver Transpl (2008) 1.97
Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res (2005) 1.94
Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res (2005) 1.93
Specificity, selection and significance of gene amplifications in cancer. Semin Cancer Biol (2006) 1.86
NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am J Surg Pathol (2005) 1.82
Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. Int J Cancer (2006) 1.78
Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol (2004) 1.78
Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol (2012) 1.76
Do testicular seminoma and nonseminoma share the same etiology? Evidence from an age-period-cohort analysis of incidence trends in eight European countries. Cancer Epidemiol Biomarkers Prev (2006) 1.75
A web-based system for individualised survival estimation in breast cancer. BMJ (2003) 1.70
Second cancers after squamous cell carcinoma and adenocarcinoma of the cervix. J Clin Oncol (2008) 1.69
Cancer incidence in multiple sclerosis: a 35-year follow-up. Neuroepidemiology (2004) 1.69
Coverage and performance of colorectal cancer screening with the faecal occult blood test in Finland. J Med Screen (2011) 1.63
Second primary cancers in patients with nasopharyngeal carcinoma: a pooled analysis of 13 cancer registries. Cancer Causes Control (2007) 1.61
Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol (2006) 1.61
Mortality from cancer and other causes in commercial airline crews: a joint analysis of cohorts from 10 countries. Occup Environ Med (2014) 1.61
Considerations of circadian impact for defining 'shift work' in cancer studies: IARC Working Group Report. Occup Environ Med (2010) 1.60
Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. Hepatology (2008) 1.59
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Long-term risk of end stage renal disease in patients with posterior urethral valves. J Urol (2011) 1.57
Second primary cancers in thyroid cancer patients: a multinational record linkage study. J Clin Endocrinol Metab (2006) 1.54
Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res (2008) 1.53
Taxanes and anthracyclines in early breast cancer: which first? Lancet Oncol (2010) 1.53
Incidence of cancer and statin usage--record linkage study. Int J Cancer (2010) 1.51
Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Mol Cancer Res (2006) 1.51
Survival from rare cancer in adults: a population-based study. Lancet Oncol (2006) 1.49
Acute liver failure after valproate exposure in patients with POLG1 mutations and the prognosis after liver transplantation. Liver Transpl (2014) 1.48
Biliary dysplasia in patients with primary sclerosing cholangitis: additional value of DNA ploidity. Liver Int (2011) 1.48
Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: retrospective cohort study. BMJ (2005) 1.47
Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis. J Clin Rheumatol (2008) 1.46
Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia (2014) 1.46
Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer. BMC Clin Pathol (2011) 1.46
Risk of second primary cancer among patients with head and neck cancers: A pooled analysis of 13 cancer registries. Int J Cancer (2008) 1.44
Merkel cell polyomavirus infection, large T antigen, retinoblastoma protein and outcome in Merkel cell carcinoma. Clin Cancer Res (2011) 1.44
Prognostic significance of tumor-associated trypsin inhibitor (TATI) and human chorionic gonadotropin-β (hCGβ) in patients with hepatocellular carcinoma. Scand J Gastroenterol (2013) 1.44
Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project. Haematologica (2011) 1.43
Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med (Berl) (2006) 1.43
Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. J Pathol (2005) 1.43
Interpreting international comparisons of cancer survival: the effects of incomplete registration and the presence of death certificate only cases on survival estimates. Eur J Cancer (2007) 1.43
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res (2011) 1.42
Cholangiocarcinoma among workers in the printing industry: using the NOCCA database to elucidate the generalisability of a cluster report from Japan. Occup Environ Med (2013) 1.42
Cancer survival in a southern African urban population. Int J Cancer (2004) 1.41
Risk of second cancer among women with breast cancer. Int J Cancer (2006) 1.41
[A certain increase of skin cancer among pilots]. Lakartidningen (2003) 1.41
Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev (2004) 1.39
Exposure to benzene at work and the risk of leukemia: a systematic review and meta-analysis. Environ Health (2010) 1.39
Late hepatic artery thrombosis after pediatric liver transplantation: a cross-sectional study of 34 patients. Liver Transpl (2014) 1.38
Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. J Natl Cancer Inst (2013) 1.38
Association of Wwox with ErbB4 in breast cancer. Cancer Res (2007) 1.37
Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group. Cancer (2007) 1.36